Cowen’s Oliver Chen and team call Signet Jewelers (SIG) a “‘must have’ stock” following yesterday’s earnings. They explain why:
SCOTT EELLS/BLOOMOBERG NEWS
We continue to see multiple positive catalysts of sales & earnings growth over the long-term, including: agile leverage of proprietary brand portfolio (~31% of mix), inelastic bridal demand (50% of mix), and a healthy middle income consumer. Near-term, we’re encouraged by mgmt. confidence in the business with FY17 outlook for top & bottom line exceeding expectations. We acknowledge FY17 comp guide implies a 2H acceleration, but still appears achievable on: 1) momentum continuing to build with the Ever Us collection compounded by new line extensions (e.g. earrings & bracelets); 2) roll-out of Pandora shop-in-shops + new Chosen Diamond program; 3) further refining of marketing campaigns; 4) Zales synergies; and 5) cont’d investments in store ops/sales training. In terms of profitability, mgmt. expects both GM and SG&A leverage to drive strong earnings flow during the year, with GM improvement driven by higher sales & synergies, while SG&A leverage expected to flow due to marketing & organizational design efficiencies. Reit. Outperform on SIG with $165PT on 17x FY18 EPS.
Best Income Stocks To Buy Right Now: Myriad Genetics, Inc.(MYGN)
Myriad Genetics, Inc. (Myriad), incorporated on November 6, 1992, is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Myriad offers diagnostic tests for a range of dise ases, such as Myriad myRisk Hereditary Cancer test for hereditary breast cancer, hereditary ovarian cancer, hereditary pancreatic cancer, hereditary uterine (endometrial) cancer and hereditary colon cancer; Myriad myPlan Lung Cancer test for lung cancer; Myriad myPath Melanoma test for melanoma; Prolaris test for prostate cancer, and Vectra DA for rheumatoid arthritis (RA).
Molecular Diagnostic Testing
The Company’s molecular diagnostic tests are designed to analyze genes, their expression levels and corresponding proteins. Myriad’s primary molecular diagnostic tests include myRisk Hereditary Cancer, a deoxyribonucleic acid (DNA) sequencing test for assessing the risks for hereditary cancers, such as breast cancer, ovarian cancer, colon cancer, uterine cancer, melanoma, pancreatic cancer, prostate cancer and gastric cancer; BRACAnalysis, a DNA sequencing test for assessing the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx ! , a DNA sequencing test for use as a companion diagnostic with the poly (ADP-ribose) polymerase (PARP) inhibitor LynparzaTM (olaparib); Tumor BRACAnalysis CDx, a DNA sequencing test designed to be utilized to predict response to DNA damaging agents, such as platinum-based chemotherapy agents and PARP inhibitors; COLARIS, a DNA sequencing test for assessing the risk of colorectal and uterine cancer; COLARIS AP, a DNA sequencing test for assessing the risk of colorectal cancer; Vectra DA, a protein detection test for assessing the disease activity of rheumatoid arthritis; Prolaris, a ribonucleic acid (RNA) expression test for assessing the aggressiveness of prostate cancer; EndoPredict, an RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, an RNA expression test for diagnosing melanoma, and myPlan Lung Cancer, an RNA expression test for assessing the aggressiveness of lung cancer.
Pharmaceutical and Clinical Services
The Company provides a range of pharmaceutical and clinical services. Through its subsidiary, Myriad RBM, Inc., Myriad provides biomarker discovery and pharmaceutical and clinical services to the pharmaceutical, biotechnology and medical research industries utilizing its multiplexed immunoassay technology. The Company also owns Privatklinik Dr. Robert Schindlbeck GmbH & Co. KG, located approximately 15 miles from the Company’s European laboratories in Munich, Germany. The Company’s technology enables it to screen sets of well-characterized clinical samples from both diseased and non-diseased populations against its menu of biomarkers.
- [By Ben Levisohn]
We took in Walt Disney (DIS) earnings, Argus’ downgrade of Noble (NE), and Myriad Genetics’ (MYGN) freefall.
We looked at the speculation that International Paper (IP) could be a takeover target, and the progress made at Ralph Lauren (RL), and the slowing same-store sales at Shake Shack (SHAK).
Best Income Stocks To Buy Right Now: Insulet Corporation(PODD)
Insulet Corporation, a medical device company, develops, manufactures, and sells insulin infusion systems for people with insulin-dependent diabetes in the United States. The company offers OmniPod Insulin Management System (OmniPod System), which consists of the OmniPod, an easy-to-use continuous insulin delivery system for people with insulin-dependent diabetes; and personal diabetes manager, a handheld wireless device. It also sells blood glucose testing supplies, insulin pumps, pump supplies, pharmaceuticals, and other products for the management and treatment of diabetes. The company sells and markets its OmniPod System through a combination of direct sales representatives and independent distributors. Insulet Corporation was founded in 2000 and is headquartered in Billerica, Massachusetts.
- [By James Brumley]
And just for the record, theme-based buyout speculation doesn’t improve your chances of picking an acquisition target. Back in 2012 after Bristol-Myers Squibb (BMY) bought Amylin for control of its diabetes pipeline following the purchase of Neighborhood Diabetes by Insulet (PODD), pundits were sure it would spark a wave of other diabetes-driven acquisitions. Those other M&A candidates began getting bid up, but as it turns out, no more meaningful buyouts materialized in the diabetes space.
Top 5 Prefered Companies To Own For 2016: SanDisk Corporation(SNDK)
Sandisk Corporation designs, develops, and manufactures NAND flash memory storage solutions that are used in various consumer electronics products. The company offers removable cards under the SanDisk Ultra, SanDisk Extreme, and SanDisk Extreme PRO brands; embedded products under the iNAND brand; universal serial bus (USB) flash drives under the Cruzer brand; digital media players under the Sansa brand; solid state drives under the Lightning brand; and wafers and memory components. Its removable card products are used in a range of consumer electronics devices, including mobile phones, digital cameras, gaming devices, and laptop computers; and embedded flash products are used in mobile phones, tablets, ultrabooks, eReaders, global positioning system devices, gaming systems, imaging devices, and computing platforms. The company also provides high-capacity storage solutions, such as solid-state drives that are used in lieu of hard disk drives. It offers its products to the m obile phone, consumer electronics, and computing end markets through original equipment manufacturers, distributors, and retail sales channels in the Americas, the Asia Pacific, Europe, the Middle East, Africa, and Japan. The company was formerly known as SunDisk Corporation and changed its name to SanDisk Corporation in August 1995. SanDisk Corporation was founded in 1988 and is headquartered in Milpitas, California.
- [By Michael Flannelly]
Early on Friday, analysts at RBC Capital boosted the near-term estimates on SanDisk Corporation (SNDK), a manufacturer of data storage products, because a fire at SK Hynix’s factory should lead to favorable pricing over the next two quarters.
“We see a favorable pricing environment as a result of SK Hynix’s fire, which threatens to curtail NAND output as the company likely re-purposes production back toward DRAM, resulting in lower than expected incremental NAND wafers vs. company’s plan of 170K/WPM,” RBC Capital analyst Freedman said. “Consequently, we see stronger pricing through EoY before SK Hynix ramps NAND toward normalized prod’t levels as DRAM resources are restored/replaced.”
The analysts maintain an “Outperform” rating on SDNK and still see shares reaching $76. This price target suggests a 26% upside to the stock’s Thursday closing price of $60.08. Furthermore, they boosted SanDisk’s 2013 EPS estimates from $4.82 to $4.95.
SanDisk shares were up a fraction during pre-market trading on Friday. The stock is up 38.11% year-to-date.